You are here: Homepage Juridische Onderwerpen Intellectueel Eigendom
Ingediend: 19 April 2018
In this article, we recap on the earlier Teva v EMA decision and summarise the recent outcome in Shire v EMA. We have also included relevant parts of the Regulation 141/2000 on Orphan Medicinal Products in the Annex hereto.
Ingediend: 18 April 2018
Part three of a six part series reviewing the patent litigation landscape in Europe - Patent litigation in France.
Ingediend: 16 April 2018
The court’s recent decisions in Illumina, Inc & Ors v Premaitha Health Plc & Ors  EWHC 2930 (Pat) and Oxford Nanopore Technologies & Anor v Pacific Biosciences of California, Inc & Anor  EWHC 3190 (Pat) serve as a helpful reminder as to how the court will assess whether a licence is truly “exclusive” for the purposes of section 130(1) of the Patent Act 1977.
Ingediend: 11 April 2018
Part two of a six part series reviewing the patent litigation landscape in Europe - Patent litigation in the United Kingdom.
Ingediend: 04 April 2018
Part one of a six part series reviewing the patent litigation landscape in Europe - Patent litigation in Germany.
Ingediend: 27 March 2018
This article reviews the latest referrals to the CJEU on the intepretation of the SPC Regulation, in particular what it means for a product to be "protected" by a patent under Article 3(a).
Ingediend: 19 March 2018
Articles 50-57 of the draft Withdrawal Agreement outline the EU Commission’s position on the protection of EU intellectual property rights in the UK post-Brexit, which largely aligns with the Commission’s September 2017 position paper and the UK government’s 06 March 2018 technical note on Brexit separation issues.
Datum: 17 May 2018
This sector focused training day offers you the chance to hear about a broad range of topics relevant to the TMT sector from lawyers and external specialists who regularly advise on TMT related issues.
Ingediend: 05 March 2018
During the second half of 2017, two important decisions have clarified the validity requirements for a supplementary protection certificate (hereinafter “SPC”) on a combination of active ingredients.
Ingediend: 21 February 2018
Au cours du dernier semestre de l’année 2017, deux décisions sont venues apporter des éclaircissements importants sur les conditions de validité d’un certificat complémentaire de protection (ci-après « CCP ») portant sur une combinaison de principes actifs.
Podcast 607: Business protection: Cybersecurity
Laat alle videopodcasts zien
Londen 17 May 2018
Laat alles zien
bekijk alle trainingsmateriaal
© Simmons & Simmons LLP 2018. All rights reserved. Registered in England & Wales Registered Number OC352713
elexica Limited, CityPoint, One Ropemaker Street, London EC2Y 9SS T: +44 20 7628 2020